Nootropic
Adrafinil
SaveA prodrug of modafinil that is converted in the liver to its active metabolite. Originally developed in France for narcolepsy-related drowsiness.
Quick verdict
Functionally equivalent to modafinil after hepatic conversion, but adds liver-load concerns and slower onset.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Clinical data from the 1980s–90s in elderly patients with vigilance disorders. Largely superseded by modafinil itself. Hepatotoxicity monitoring was recommended during original prescribing.
Benefits
- Promotes wakefulness via modafinil conversion
- Available without prescription in some jurisdictions
- May improve vigilance in sleep-deprived states
Dosage notes
Historically 600–1200 mg/day in divided doses. Higher doses than modafinil are required due to incomplete conversion.
Side effects
- Elevated liver enzymes with chronic use
- Headache
- Nausea
- Insomnia if dosed late
Who should be cautious
Hepatotoxicity risk with chronic use — liver enzymes should be monitored. Not available by prescription in most countries.
What this page cannot tell you
Most relevant clinical evidence actually pertains to modafinil. Adrafinil-specific human data is older and sparser.
Leaderboard scores
- Focus65
- Energy65
- Mood35
Write a review
Sign in to write a review.